Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies-Reference-Cited by-同舟云学术

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies

Published:2018-02-02 Issue:4 Volume:97 Page:617-627
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Kiladjian Jean-Jacques,Guglielmelli Paola,Griesshammer Martin,Saydam Guray,Masszi Tamas,Durrant Simon,Passamonti Francesco,Jones Mark,Zhen Huiling,Li Jingjin,Gadbaw Brian,Perez Ronco Julian,Khan Mahmudul,Verstovsek Srdan

Funder

Novartis (CH); Novartis Pharmaceuticals Corporation

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-017-3225-1/fulltext.html

Reference30 articles.

1. Griesshammer M, Gisslinger H, Mesa R (2015) Current and future treatment options for polycythemia vera. Ann Hematol 94(6):901–910. https://doi.org/10.1007/s00277-015-2357-4

2. Vannucchi AM (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(17):1670–1671. https://doi.org/10.1056/NEJMc1502524

3. Hensley B, Geyer H, Mesa R (2013) Polycythemia vera: current pharmacotherapy and future directions. Expert Opin Pharmacother 14(5):609–617. https://doi.org/10.1517/14656566.2013.779671

4. Reiter A, Harrison C (2016) How we identify and manage patients with inadequately controlled polycythemia vera. Curr Hematol Malig Rep 11(5):356–367. https://doi.org/10.1007/s11899-016-0311-8

5. Stein BL, ST O, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, Hoffman R (2015) Polycythemia vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F. J Clin Oncol 33(33):3953–3960. https://doi.org/10.1200/JCO.2015.61.6474

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera;Clinical Lymphoma Myeloma and Leukemia;2023-11

2. Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices;Annals of Hematology;2023-03-21

3. Primary Arterial Hypertension and Drug-Induced Hypertension in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review;Biomedicines;2023-01-28

4. JAK Inhibitors for the Management of Myeloproliferative Neoplasms;Pathogenesis and Treatment of Leukemia;2023

5. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations;The Lancet Haematology;2022-04